Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics plc - Special Call Transcript

Sep 18, 2020 / 12:00PM GMT
Release Date Price: $14.28 (+2.00%)
Operator

Good day, and welcome to the Autolus Therapeutics ESMO Investor Conference Call. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Lucinda Crabtree, Vice President, Investor Relations. Please go ahead.

Lucinda Crabtree
Autolus Therapeutics plc - VP of IR & Corporate Communications

Thank you, Cole. Good morning or good afternoon, everyone, and thank you for taking part in today's call on the ESMO AUTO3 Phase I/II data update. I'm Lucinda Crabtree, Vice President of Investor Relations. With me today are Dr. Christian Itin, our Chairman and Chief Executive Officer; Dr. Robert Chen, our AUTO3 and lymphoma program lead; Dr. Nushmia Khokhar, our lead -- Head of Clinical Development; Brent Rice, our Chief Commercial Officer; and Andrew Oakley, our Chief Financial Officer.

Before we begin, I would like to remind you that during today's call, our discussion today will contain forward-looking statements. All statements other than statements of historical facts on this call are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot